To biopsy or not to biopsy: Is that the only question?

Oncologist

Volumn 17, Issue 2, 2012, Pages 151-153

  Dawood, Shaheenah ^a   Gonzalez Angulo, Ana M ^b  

^a DUBAI HOSPITAL   (United Arab Emirates)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROGESTERONE RECEPTOR; TRASTUZUMAB;

BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; HUMAN; HUMAN TISSUE; NOTE; PRIMARY TUMOR; PRIORITY JOURNAL; RECEPTOR SENSITIVITY;

BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84930481830     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0432     Document Type: Note

References (11)

1. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
2. Miller KD, Sledge GW Jr. The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 1999;13:415-434.
3. Dawood S, Broglio K, Buzdar AU et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutionalbased review. J Clin Oncol 2010;28:92-98.
4. Pusztai L, Viale G, Kelly CM et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. The Oncologist 2010; 15:1164-1168.
5. Macfarlane R, Seal M, Speers C et al. Molecular alteration between the primary breast cancer the subsequent locoregional/metastatic tumor. The Oncologist 2012;17:172-178.
6. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2011 Nov 28 [Epub ahead of print].
7. Niikura N, Liu J, Hayahi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2011 Nov 28 [Epub ahead of print].
8. Mittendorf EA, Wu Y, Scaltriti M et al. Loss of HER2 amplification following trastuzumabbased neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009;15:7381-7388.
9. Weigelt B, Glas AM, Wessels LF et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100:15901-15905.
10. Wu JM, Fackler MJ, Halushka MK et al. Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008;14:1938-1946.
11. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf, accessed November 20, 2011.